


The FDA's Pediatric Device Consortia Grant Program 2013 Fact Sheet

FDA has awarded its third round of grants to Pediatric Device Consortia which advance the development of pediatric medical devices through the establishment of consortia providing advisory services.

The consortia each bring together teams with excellence and expertise in delivering business, regulatory, legal, scientific, engineering, and clinical services for children.


In addition to business and regulatory advising, the consortia's device development services include intellectual property advising, prototyping, engineering, laboratory and animal testing, grant writing, and clinical trial design. The consortia will provide advice on Federal and non-Federal funding resources.

Consortia support pediatric medical device progression through all stages of development—concept formation, prototyping, preclinical, clinical, manufacturing, marketing, and commercialization.



Along the way, the consortia will work collaboratively with the Food and Drug Administration help innovators effectively navigate existing laws, regulations, and agency guidance to protect the health and safety of children.

FY 2013 PEDIATRIC DEVICE CONSORTIA GRANTEES:



- University of Michigan Pediatric Device Consortium, led by James Geiger, M.D., \$700,000
- Atlantic Pediatric Device Consortium, led by David Ku, M.D., Ph.D., and Barbara Boyan, Ph.D., \$700,000
- National Capital Consortium for Pediatric Device Innovation, led by Peter Kim, M.D., Ph.D., \$700,000
- New England Pediatric Device Consortium, led by Rick Greenwald, Ph.D., \$700,000
- Southern California Center for Technology and Innovation in Pediatrics, led by Yaniv Bar-Cohen, M.D. and Chester Koh, M.D., \$300,000
- Philadelphia Regional Pediatric Medical Device Consortium, led by Matthew Maltese, M.S., Ph.D., \$300,000
- Boston Pediatric Device Consortium, led by Pedro del Nido, M.D., \$200,000

The program is administered by the FDA's Office of Orphan Products Development. Contacts in OOPD: Linda.Ulrich@fda.hhs.gov and Debra.Lewis@fda.hhs.gov